Market Overview:
The global autoimmune and inflammatory immunomodulators market is expected to grow at a CAGR of 7.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of autoimmune diseases, rising awareness about available treatment options, and technological advancements in the field of autoimmune therapies. The global autoimmune and inflammatory immunomodulators market is segmented on the basis of type into biologics and small molecules. The biologics segment is further sub-segmented into monoclonal antibodies (mAbs), fusion proteins, cytokines, TNF inhibitors, and others (insulin analogs). On the basis of application, the global autoimmune.
Product Definition:
Autoimmune and Inflammatory Immunomodulators are drugs that help to regulate the immune system. They are important because they can help to control autoimmune diseases and inflammation.
Biologics:
Biologics, also known as biological drugs or biopharmaceuticals are living organisms which are used to treat the disease. It's main function is to help the body's immune system by fighting with foreign objects that cause damage to the body cells. Biologics can either be derived from living organisms (e.g., antibodies) or artificial intelligence technology (e.g., monoclonal antibodies).
The global autoimmune.
Small Molecules:
Small molecules are the chemical compounds that make up a large part of our lives. They are found in every day products such as air, food, water and medicine. Small molecules can also be created by humans but only in very small amounts for example; nicotine is a small molecule that is used as an additive to tobacco products.
Application Insights:
Rheumatoid arthritis dominated the global market in terms of revenue in 2017. The disease is a chronic one and affects more than 20 million people across the globe. It is also considered to be one of the most common diseases affecting older adults, as it was observed that around 60% of patients diagnosed with RA are above 60 years old.
The European Society for Rheumatology (ESR) reported that around 54,000 people developed arthritis due to rheumatic conditions in 2015, while about 1.5 million were diagnosed with RA during the same year globally. Thus, increasing incidence rates are expected to fuel demand over the forecast period from 2018 to 2030.
Regional Analysis:
North America dominated the global market in 2017. The presence of key players, favorable reimbursement policies, and increasing prevalence of autoimmune diseases are some factors attributing to its large share. In addition, growing awareness about these immunomodulators is also expected to drive the region’s growth over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising healthcare expenditure and improving healthcare infrastructure in emerging countries such as China and India. Moreover, an increase in disposable income will also contribute towards this regional market’s development over the next eight years due to a rise in demand for auto-immune disease treatment drugs from emerging economies such as Japan and China that have high purchasing power parity (PPP). ‰vitamins A & D: Powerful Allies For Autoimmune Disease Treatment© 2018 by Modern Nutrition Pty Ltd.
Growth Factors:
- Increasing incidence of autoimmune diseases: The global autoimmune and inflammatory immunomodulators market is expected to grow at a CAGR of 5.5% during the forecast period due to the increasing incidence of autoimmune diseases such as rheumatoid arthritis, Crohn’s disease, psoriasis, and ulcerative colitis.
- Growing awareness about available treatment options: There is a growing awareness among patients about the available treatment options for various autoimmune diseases which is driving the demand for autoimmune and inflammatory immunomodulators products.
- Technological advancements in product offerings: The players in this market are constantly investing in research and development activities to introduce new technologies and products that can address unmet needs of patients with various types of autoimmune diseases. This is helping them to gain a larger share in this market.
- Rising number of mergers & acquisitions: The players operating in this market are indulging themselves into strategic partnerships and acquisitions to expand their product portfolios as well as geographical presence across different regions worldwide thereby strengthening their position in this market space . For instance, In March 2017, Pfizer acquired Anacor Pharmaceuticals Inc., a company focused on developing novel small-molecule therapeutics targeting autoinflammatory disorders such as eczema (atopic dermatitis) and psoriasis). This acquisition helped Pfizer expand its pipeline offerings for treating autoinflammatory disorders while gaining access to Anacor’s late-stage product
Scope Of The Report
Report Attributes
Report Details
Report Title
Autoimmune and Inflammatory Immunomodulators Market Research Report
By Type
Biologics, Small Molecules
By Application
Rheumatoid Arthritis, IBD
By Companies
AbbVie, Johnson & Johnson, Amgen, F. Hoffmann-La Roche, Pfizer, AstraZeneca, Avaxia Biologics, Biogen Idec, Bristol-Myers Squibb, Boehringer Ingelheim, AbbVie, Enlivex Therapeutics, Gilead Sciences
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
242
Number of Tables & Figures
170
Customization Available
Yes, the report can be customized as per your need.
Global Autoimmune and Inflammatory Immunomodulators Market Report Segments:
The global Autoimmune and Inflammatory Immunomodulators market is segmented on the basis of:
Types
Biologics, Small Molecules
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Rheumatoid Arthritis, IBD
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- AbbVie
- Johnson & Johnson
- Amgen
- F. Hoffmann-La Roche
- Pfizer
- AstraZeneca
- Avaxia Biologics
- Biogen Idec
- Bristol-Myers Squibb
- Boehringer Ingelheim
- AbbVie
- Enlivex Therapeutics
- Gilead Sciences
Highlights of The Autoimmune and Inflammatory Immunomodulators Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Biologics
- Small Molecules
- By Application:
- Rheumatoid Arthritis
- IBD
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Autoimmune and Inflammatory Immunomodulators Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Autoimmune and inflammatory immunomodulators are medications that help the body’s immune system to fight off infections. They can be used to treat a variety of conditions, including rheumatoid arthritis, psoriasis, lupus erythematosus (lupus), and multiple sclerosis.
Some of the major players in the autoimmune and inflammatory immunomodulators market are AbbVie, Johnson & Johnson, Amgen, F. Hoffmann-La Roche, Pfizer, AstraZeneca, Avaxia Biologics, Biogen Idec, Bristol-Myers Squibb, Boehringer Ingelheim, AbbVie, Enlivex Therapeutics, Gilead Sciences.
The autoimmune and inflammatory immunomodulators market is expected to register a CAGR of 7.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Autoimmune and Inflammatory Immunomodulators Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Autoimmune and Inflammatory Immunomodulators Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Autoimmune and Inflammatory Immunomodulators Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Autoimmune and Inflammatory Immunomodulators Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Autoimmune and Inflammatory Immunomodulators Market Size & Forecast, 2020-2028
4.5.1 Autoimmune and Inflammatory Immunomodulators Market Size and Y-o-Y Growth
4.5.2 Autoimmune and Inflammatory Immunomodulators Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Biologics
5.2.2 Small Molecules
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Rheumatoid Arthritis
6.2.2 IBD
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Autoimmune and Inflammatory Immunomodulators Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Autoimmune and Inflammatory Immunomodulators Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Biologics
9.6.2 Small Molecules
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Rheumatoid Arthritis
9.10.2 IBD
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Biologics
10.6.2 Small Molecules
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Rheumatoid Arthritis
10.10.2 IBD
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Biologics
11.6.2 Small Molecules
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Rheumatoid Arthritis
11.10.2 IBD
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Biologics
12.6.2 Small Molecules
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Rheumatoid Arthritis
12.10.2 IBD
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Biologics
13.6.2 Small Molecules
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Rheumatoid Arthritis
13.10.2 IBD
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Autoimmune and Inflammatory Immunomodulators Market: Competitive Dashboard
14.2 Global Autoimmune and Inflammatory Immunomodulators Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 AbbVie
14.3.2 Johnson & Johnson
14.3.3 Amgen
14.3.4 F. Hoffmann-La Roche
14.3.5 Pfizer
14.3.6 AstraZeneca
14.3.7 Avaxia Biologics
14.3.8 Biogen Idec
14.3.9 Bristol-Myers Squibb
14.3.10 Boehringer Ingelheim
14.3.11 AbbVie
14.3.12 Enlivex Therapeutics
14.3.13 Gilead Sciences
